Abstract:
PURPOSE OF THE STUDY:Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. PATIENTS AND METHODS:MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. RESULTS:It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. CONCLUSIONS:Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.
journal_name
Curr Res Transl Medjournal_title
Current research in translational medicineauthors
Lisini D,Nava S,Pogliani S,Avanzini MA,Lenta E,Bedini G,Mantelli M,Pecciarini L,Croce S,Boncoraglio G,Maccario R,Parati EA,Frigerio Sdoi
10.1016/j.retram.2018.06.002subject
Has Abstractpub_date
2019-02-01 00:00:00pages
20-27issue
1issn
2452-3186pii
S2452-3186(18)30034-5journal_volume
67pub_type
杂志文章abstract::Graft-versus-host disease (GvHD) is a common complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with high morbidity and mortality rates. The purpose of this study was to demonstrate the efficacy of Manual Lymph Drainage (MLD) and a home-based exercise programme on range of motion (ROM) and ...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2019.11.001
更新日期:2020-01-01 00:00:00
abstract::The development of genomic editing technologies expands the landscape of T cell engineering for adoptive cell therapy. Among the multiple tools that can be used, CRISPR/Cas9 has been shown to be relatively easy to use, simple to design and cost effective with highly efficient multiplex genome engineering capabilities....
journal_title:Current research in translational medicine
pub_type: 杂志文章,评审
doi:10.1016/j.retram.2018.04.003
更新日期:2018-05-01 00:00:00
abstract::Based on animal studies and serendipitous clinical cases, haematopoietic stem cell transplantation (HSCT) has been used since 1995 as a specific treatment for patients with severe treatment-resistant autoimmune disease (ADs). Despite other clinical developments for autoimmune diseases, including biological therapies, ...
journal_title:Current research in translational medicine
pub_type: 杂志文章,评审
doi:10.1016/j.retram.2016.03.003
更新日期:2016-04-01 00:00:00
abstract::Hyper IgM (HIGM) syndromes are a complex of primary immunodeficiency disorders. A 4-years-old boy with recurrent fever and chills, dyspnea, sort throat for a month was admitted to emergency department. In the current case, whole exome sequencing followed by Sanger sequencing were employed in order to screen probable f...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2018.02.001
更新日期:2019-02-01 00:00:00
abstract:PURPOSE OF THE STUDY:Two chimeric antigen receptor (CAR) T-cell therapies - Tisagenlecleucel (Kymriah™) and Axicabtagene ciloleucel (Yescarta™) - have been approved for commercial use. In order to inform forthcoming EBMT guidelines on the management of adults and children undergoing autologous CAR T-cell therapy, we un...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2019.05.002
更新日期:2019-08-01 00:00:00
abstract::Research into how the central nervous system (CNS) and the skin of mammals are physiologically connected and how this "brain-skin connection" may be therapeutically targeted in clinical medicine has witnessed a renaissance. A key element in this development has been the discovery that mammalian skin and its appendages...
journal_title:Current research in translational medicine
pub_type: 杂志文章,评审
doi:10.1016/j.retram.2016.10.003
更新日期:2016-01-01 00:00:00
abstract:PURPOSE OF THE STUDY:While acute graft-versus-host-disease (GVHD) is a T cell-mediated disease caused by alloreactive donor T cells, we and others have highlighted that patients who received higher proportion of donor CD4+ naïve and central memory T cells expressing the chemokine receptor 7 (CCR7) more often developed ...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2018.11.002
更新日期:2019-02-01 00:00:00
abstract::Studies have shown that the NRF-2 /HO-1 pathway participates in myocardial ischemic reperfusion injury (MI/R) and that Geniposide (GEN) could protect the myocardial against MI/R. This study aims to examine the protective effects of GEN on MI/R in diabetic rats and further explore the possible mechanism of action. Duri...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2019.03.002
更新日期:2019-05-01 00:00:00
abstract::Diabetic retinopathy (DR) and retinopathy of prematurity (ROP) present two examples of proliferative retinopathy, characterized by the same stages of progression; ischemia of the retinal vessels, leads to hypoxia and to correct the problem there is the setting up of uncontrolled angiogenesis, which subsequently causes...
journal_title:Current research in translational medicine
pub_type: 杂志文章,评审
doi:10.1016/j.retram.2019.01.005
更新日期:2019-05-01 00:00:00
abstract::Heterogeneous practices exist across transplant centres regarding assessment prior to allogeneic haematopoietic cell transplantation (allo-HCT) for myelofibrosis, post-transplant monitoring and management of relapse. The 'Practice Harmonisation and Guidelines' and Myeloproliferative Neoplasms subcommittees of the Chro...
journal_title:Current research in translational medicine
pub_type: 杂志文章
doi:10.1016/j.retram.2020.08.003
更新日期:2020-10-15 00:00:00